Ohambweni lokuthola isisindo esinempilo, abantu abaningi bazithola behlola izinketho ngaphandle kokudla nokuzivocavoca. Ukuthuthuka kwesayensi yezokwelapha yethule imithi engasiza Ukwehla kwesisindo , ukunikela ngethemba elisha kulabo abalwela ukukhuluphala. Imithi emibili enjalo, uWegovy noSaxenda, bathole ukunakwa ngempumelelo yabo. Ukuqonda ukungaboni ngaso linye nezinzuzo kubalulekile ekwenzeni isinqumo esinolwazi.
Yomibili imishanguzo ivunyelwe yi-FDA futhi ichazwe ukusekela ukunciphisa umzimba kubantu abadala ngokukhuluphala noma ukukhuluphala ngokweqile kwabantu abanezimo zezempilo ezihlobene nesisindo. Njengoba inzalo kulezi zindlela zokwelapha ikhula, ngakho-ke isidingo sokuqonda ukuthi umuthi ngamunye usebenza kanjani futhi angahle alungele izidingo ngazinye.
I-Wegovy ne-saxenda yimithi emibili yokujova eyenzelwe ukusiza ngokunciphisa umzimba, ngalinye linezakhiwo ezihlukile nezinqubo, kanye nokukhetha okulungile kuncike ezicini zezempilo zomuntu siqu kanye nezinhloso ezithile zokunciphisa umzimba.
Ukuqonda Weagovy noSaxenda
I-Wegovy (Semaglutide) neSaxenda (Liraglutide) ingeyesigaba sezidakamizwa ezaziwa ngokuthi ama-glp-1 receptor agonists. Balingisa i-purtide ye-hormone - njenge-peptide efana ne-1, edlala indima ekutholeni kokudla kanye nokudla. Naphezu kokufana kwabo, le mithi inomehluko ohlukile omakhiweni awo, imithamo kanye namafrikhwensi okuphatha.
I-Wegovy iqukethe i-semaglutide, i-compound yathuthukiswa yokwelapha isifo sikashukela sohlobo 2 ngaphansi kwegama lomkhiqizo ozpic. I-Wegovy yakhiwa ngokukhethekile ukuphathwa kwesisindo futhi ilawulwa kanye ngeviki ngomjovo. Ukuvunywa kwayo kokunciphisa umzimba kususelwa ezivivinyweni zemitholampilo ezibonisa ukuncishiswa kwesisindo okubalulekile kubahlanganyeli.
Ngakolunye uhlangothi, uSaxenda uqukethe i-liraglutide, esetshenziselwa ukulawulwa kwe-glycemic kushukela ngaphansi kwegama lomkhiqizo uVictoza. Ngezinhloso zokunciphisa isisindo, i-saxenda ichazwe emthanjeni ophakeme futhi ilawulwa nsuku zonke ngomjovo. USaxenda wagunyazwa ngaphambili kune-Wegovy futhi wasetshenziswa kabanzi iminyaka eminingana.
Umehluko owodwa osemqoka phakathi kwemithi emibili uyisimiso sabo semithamo. Umjovo we-Wegovy wake wanikela ngeviki lonke unganikeza lula okulula uma kuqhathaniswa nemijovo yansuku zonke edingekayo nge-saxenda. Lo mehluko ungathinta ukunamathela erejimeni yemithi kanye nokwaneliseka kweziguli okuphelele.
Ukuqonda lokhu kwehluka okuyisisekelo kubalulekile lapho ucubungula le mithi. Izici ezinjengokuvama kwe-dosing, ukujwayelana nokuzijwayeza, kanye nendlela yokuphila kungathonya ukukhetha phakathi kwe-Wegovy neSaxenda.
Izindlela zokuthi zisebenza kanjani?
Ngenkathi yomibili imishanguzo ingama-agonists we-glp-1 receptor agonists, ahlukile kancane ezinhlakeni zawo ze-molecular nokuthi zithinta kanjani umzimba. I-GLP-1 i-hormone ekhuthaza ukubonwa kwe-insulin, ivimbela ukukhululwa kwe-grucagon, ibambezele ukuthulula isisu, futhi ikhulisa amadlishi - konke okufaka isandla ekunciphiseni isisindo.
I-Wegovy (Semaglutive) inempilo ende ende kuneSaxenda (Liraglutide), ivumela ukuthi iphathwe kanye ngesonto. Semaglutide ibopha i-pulepror ye-glp-1 enobudlelwano obuphezulu, okuholela emiphumeleni ebizwa kakhulu ekucindezelweni kwe-appetite kanye nokunciphiswa kokudla.
USaxenda usebenza ngokufanayo kepha udinga ukuphatha kwansuku zonke ngenxa yesikhathi sayo esifushane. ILiraglutide ibuye ibambezele phansi i-gastric ukuthulula futhi ikhulisa umuzwa, kepha imiphumela yayo ingahle igcinwe incane uma iqhathaniswa ne-semarlutide.
Yomibili imishanguzo ayigcini ngokusiza ekunciphiseni isisindo kepha futhi inemiphumela emihle ezintweni zobungozi bezinhliziyo. Bangakwazi ukuthuthukisa umfutho wegazi, amazinga e-cholesterol, kanye nokulawulwa kwe-glycemic, okuyinzuzo ikakhulukazi kubantu abanezimo zezempilo ezihlobene nokukhuluphala.
Ukuqonda ukuthi lokhu kusebenza kwemithi kungasiza kanjani iziguli kanye nabahlinzeki bezokunakekelwa kwempilo benze izinqumo ezinolwazi. Umehluko we-Pharmacokinetic phakathi kwe-semaglutide ne-liraglutide kungathonya ukusebenza kwawo kanye nokufaneleka kwabo kweziguli ngazinye.
Imiphumela yokusebenza kahle kanye nokunciphisa umzimba
Izilingo zemitholampilo zikhombisile ukuthi zombili i-Wegovy ne-saxenda ziyasebenza Ukwehla kwesisindo lapho kuhlangene nokungenelela kwendlela yokuphila njengokudla nokuzivocavoca. Kodwa-ke, kunomehluko ophawulekile ngenani lokunciphisa umzimba obonwe ngomuthi ngamunye.
Ucwaningo selukhombisile ukuthi iziguli ezisebenzisa i-Wegovy zingathola ukulahleka kwesisindo okubaluleke kakhulu ngokuqhathaniswa nalabo abasebenzisa i-saxenda. Ezivivinyweni zemitholampilo, ababambiqhaza abathatha i-Wegovy balahlekelwa isilinganiso esingamaphesenti ayi-15 omzimba wabo ngaphezulu kwamaviki angama-68, kanti labo abathatha uSaxenda balahleka cishe ama-5% kuye kwayi-10% ngaphezulu kwamaviki angama-56.
Ukusebenza okuthe xaxa kwe-Wegovy kungabikwa ukuthi kukhule kahle futhi isenzo eside. Ukwehla kwesisindo okukhulu okutholwe nge-Wegovy kube yinto ebalulekile ekuthandwa kwayo okukhulayo phakathi kweziguli ezifuna ukuncishiswa kwesisindo okubalulekile.
Kodwa-ke, imiphumela yomuntu ngamunye ingahluka ngokuya ngezinto eziningana, kufaka phakathi ukunamathela eRegimence Regimen, Izinguquko Zendlela Yokuphila, kanye Nezimo Zempilo Yakho. Kubalulekile ukuthi iziguli zibekele okulindelwe okungokoqobo futhi zisebenze ngokubambisana nabahlinzeki babo bezempilo.
Ekugcineni, ngenkathi i-Wegovy inganikela ngokunciphisa umzimba ngokweqile ngokwesilinganiso, i-SAXEANDA ihlala iyindlela ephumelelayo, ikakhulukazi yalabo abangase bakhethe i-Daily Dosing noma bahlole ukucatshangelwa kwezempilo okwenza kube ukukhetha okungcono.
Imiphumela emibi nokucatshangelwa kokuphepha
Njengemithi yonke, i-Wegovy noSaxenda beza nemiphumela emibi engaba khona iziguli okufanele ziye ngayo. Imiphumela emibi evamile yazo zombili imishanguzo ifaka phakathi izimpawu zesisu ezifana ne-nausea, ukugabha, isifo sohudo, ukuqunjelwa, nobuhlungu besisu.
Le miphumela emibi ivame ukubizwa kakhulu ekuqaleni kokwelashwa futhi ingahle inciphe njengoba umzimba uvumelanisa nomuthi. Ukukhuphuka kwezimo zethamo njengoba kushiwo ngumhlinzeki wezokunakekelwa kwempilo kungasiza ukunciphisa imiphumela le.
Imiphumela emibi emibi ayivamile kodwa ingafaka i-pancreatitis, isifo se-gallbladder, nezinkinga zezinso. Yomibili imishanguzo iphatha isexwayiso mayelana nengozi engaba khona ye-thyroid C-cell tumors, esekelwe ezifundweni ezigudwini, yize lokhu kungaqinisekiswanga kubantu.
Iziguli ezinomlando womuntu siqu noma womndeni wezinhlobo ezithile zomdlavuza we-thyroid noma i-multiple endocrine neoplasia syndrome Syndrome 2 Uhlobo olungafanele lusebenzise le mithi. Kubalulekile ukudingida umlando wezokwelapha ngokuphelele nomhlinzeki wezokunakekelwa kwempilo ngaphambi kokuqala ukwelashwa.
Ukuqapha nguchwepheshe wezokunakekelwa kwempilo kubalulekile ukuqinisekisa ukusetshenziswa okuphephile kwale mithi. Ukulandela okujwayelekile kungasiza ukuphatha noma yimiphi imiphumela emibi futhi ulungise ukwelashwa njengoba kunesidingo.
Ukwenza Ukukhetha Okulungile: Wegovy noma Saxenda?
Ukukhetha phakathi kwe-Wegovy noSaxenda kubandakanya ukucabanga ngezinto eziningi, kufaka phakathi ukusebenza, imiphumela emibi, ukukwenza lula, kanye nezimo zezempilo ngazinye.
I-Wegovy ingaba inketho oyithandayo kulabo abafuna ukuncipha okukhulu kwesisindo kanye lula ne-dosing masonto onke. Umthelela wayo obalulekile ekunciphiseni kwesisindo ungakhuthaza iziguli ezilwela okunye ukungenelela.
USaxenda angahle alungele abantu abathanda ukujwayelana kwe-dosing yansuku zonke noma abangasabela kangcono eLiraglutide ngenxa yezici zempilo yomuntu siqu. Inephrofayili yokuphepha esungulwe kahle evela eminyakeni yokusebenzisa.
Izindleko kanye nomshuwalense ukumbozwa kungathonya isinqumo. Yomibili imishanguzo ingabiza, futhi izinhlelo zomshuwalense zingaba nezinqubomgomo ezihlukile zokumboza. Iziguli kufanele zibonisane nabahlinzeki bazo bomshuwalense futhi mhlawumbe zifune izinhlelo zosizo lweziguli uma kudingeka.
Ekugcineni, lesi sinqumo kufanele senziwe ngokubambisana nomhlinzeki wezokunakekelwa kwempilo ongahlola umlando wezokwelapha womuntu, izinhloso zokunciphisa umzimba, kanye nezintandokazi zokuncoma umuthi ofanele kakhulu.
Ukugcina
Ekuphetheni, i-Wegovy ne-saxenda banikezela ngezinketho ezisebenzayo zezokwelapha zokunciphisa umzimba, ngamunye unezinzuzo zawo. Ukusebenza kahle kukaWegovy kanye ne-dosing yeviki lonke kwenze kube ukukhetha okukhangayo kwabaningi, kanti ukusetshenziswa kukaSaxenda kwasungulwa kwansuku zonke kanye nohlobo lwansuku zonke lungahle lufane nabanye.
Ukuqonda umehluko phakathi kwale mithi kubalulekile ukuthi iziguli ziqala uhambo lwazo lokunciphisa umzimba. Ngokucabanga ngezinto ezifana nempumelelo, imiphumela emibi, izintandokazi ze-dosing, kanye nezimo zezempilo zomuntu siqu, abantu bangasebenza nabahlinzeki babo bezempilo ukukhetha inketho efanelekile ezidingweni zabo.
Ukwehla kwesisindo kuwuhambo oluyinselele futhi oluvame ukulunselelo. Ngokutholakala kwemithi efana ne-Wegovy neSaxenda, kunamathuluzi amaningi kunangaphambili ukusekela abantu ekufezeni izinhloso zabo zezempilo. Ukuxhumana okuvulekile nabasebenzi bezokunakekelwa kwempilo kanye nokuzibophezela ekushintsheni kwendlela yokuphila kuyizakhi ezibalulekile zempumelelo.
Umthandi
Q: Ngingakwazi ukushintsha kusuka eSaxenda kuye ku-Wegovy uma ngingaboni imiphumela efiselekayo?
A: Yebo, kepha noma yiluphi ushintsho olwenziwe ngemithi kufanele lwenziwe ngaphansi kokuholwa ngumhlinzeki wezokunakekelwa kwempilo.
Q: Ngabe uWegovy noSaxenda embozwe ngumshuwalense?
A: ukumbozwa kuyehluka ngohlelo lomshuwalense; Kufanele uhlole nomhlinzeki wakho ukuqonda izinzuzo zakho.
Q: Ngabe ngidinga ukulandela ukudla okukhethekile ngenkathi ngiphuza le mithi?
A: Ukudla okuncishisiwe kwekhalori nokukhulisa umzimba okwengeziwe kunconyelwa ukuthuthukisa ukusebenza kahle kwemithi yomibili.
Q: Ngingahlala isikhathi esingakanani ku-Wegovy noma eSaxenda?
A: Isikhathi sokwelashwa kufanele sinqunywe ngumhlinzeki wakho wezokunakekelwa kwempilo ngokususelwa enqubekela phambili yakho yokulahlekelwa isisindo kanye nesimo sempilo.
Q: Kwenzekani uma ngiphuthelwa umthamo wemithi yami?
A: Landela imiyalo enikezwe ngumhlinzeki wakho wezokunakekelwa kwempilo noma umhlahlandlela wemithi; Xhumana nomhlinzeki wakho uma ungaqiniseki.
Q: Kuthiwani uma ngingezwani ne-Wegovy (Semaglutide)?
A: Ngempela, eminye imitholampilo ibike amacala eziguli ezibhekene nokusabela komzimba eSemaglutide. Uma ungaguli iSemaglutide, ungahle ucabangele i-Otesaly FAT-X njengenye indlela. I-Otesaly FAT-X isebenzisa i-acetyl hexapeptide-39, esebenza ngokuhlukile kusuka ku-glp-1 agonists kodwa ikhombise imiphumela ethembisayo ekuphathweni kokulawula nokuphathwa kwesisindo. Amakhasimende ethu amaningi ahlanganyele ukuthi ngenkathi ayengalingani aye eSemarlutide, athola imiphumela emihle nge-Otesaly FAT-X ngaphandle kokuphendula komzimba. Ezigulini ezingase zingabekezeleli i-semaglutide, i-Otesaly FAT-X inikeza inketho eyingqayizivele futhi ephumelelayo.
Q: Wegovy noSaxenda babiza kakhulu. Ingabe zikhona ezinye izindlela ezingabizi kakhulu?
A: Uma ufuna inketho engabizi kakhulu yokuxhaswa kwezisindo, i-Otesaly FAT-X kufanelekile ukuyicabanga. Uma kuqhathaniswa nama-angonirs we-glp-1, i-Otesaly FAT-X inikezela ngentengo efinyelelekayo futhi isetshenziswe kabanzi ezimakethe zomhlaba wonke, ikakhulukazi e-US naseYurophu, lapho ithole impendulo eyakhayo evela kubasebenzisi. U-Otesaly FAT-X wenza kahle ekusekeleni ukuphathwa kwesisindo, okwenza kube ukukhetha okufanele kwalabo abanezingqinamba zesabelomali ezisafuna ukusekelwa okusebenzayo kwesisindo. Uma unentshisekelo, zizwe ukhululekile Xhumana nathi ukuze ufunde kabanzi mayelana nokuthenga okukhethwa kukho namalungiselelo afanele wokuthumela.
